These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21364127)

  • 1. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):165-71. PubMed ID: 21364127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
    Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
    BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    JAMA; 2009 Dec; 302(24):2679-85. PubMed ID: 20040556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
    Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
    Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
    Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
    Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
    Samuel AM; Rathi VK; Grauer JN; Ross JS
    Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):285-288. PubMed ID: 28093943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence strength in FDA premarket approval of cardiovascular devices.
    Kong DF; Hasselblad V; Krucoff MW
    JAMA; 2010 Apr; 303(16):1599-600; author reply 1600-1. PubMed ID: 20424248
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical devices; exemptions from premarket notification and reserved devices; class I--FDA. Notice.
    Fed Regist; 1998 Feb; 63(21):5387-93. PubMed ID: 10177333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA.
    Swanson MJ; Johnston JL; Ross JS
    Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015.
    Ghobadi CW; Hayman EL; Finkle JH; Walter JR; Xu S
    J Am Coll Radiol; 2017 Jan; 14(1):24-33. PubMed ID: 28061962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study.
    Phillips AT; Rathi VK; Ross JS
    JAMA Intern Med; 2016 Apr; 176(4):551-2. PubMed ID: 26902933
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization and outcomes of reinterventions in Food and Drug Administration-approved versus trial endovascular aneurysm repair devices.
    Fairman AS; Wang GJ; Jackson BM; Foley PJ; Damrauer SM; Kalapatapu V; Golden MA; Fairman RM
    J Vasc Surg; 2018 Apr; 67(4):1082-1090. PubMed ID: 29074115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cardiovascular and noncardiovascular medical device recalls.
    Somberg JC; McEwen P; Molnar J
    Am J Cardiol; 2014 Jun; 113(11):1899-903. PubMed ID: 24837271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the FDA Safety and Innovation Act on racial and gender diversity in neurosurgical device trials.
    Siddiqui N; Chiu RG; Nunna RS; Glastris G; Mehta AI
    J Neurosurg; 2022 Jan; 136(1):274-281. PubMed ID: 34171831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical device recalls and the FDA approval process.
    Zuckerman DM; Brown P; Nissen SE
    Arch Intern Med; 2011 Jun; 171(11):1006-11. PubMed ID: 21321283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
    Zheng SY; Dhruva SS; Redberg RF
    JAMA; 2017 Aug; 318(7):619-625. PubMed ID: 28810022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
    Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
    Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.